Task: rs001 | Last Updated: 2026-03-15 | Kind: priority-ranking | Total Gaps Identified: 25
The neurodegenerative disease research landscape presents stark imbalances in clinical trial investment and therapeutic development across different conditions. While Alzheimer's Disease (AD) and Parkinson's Disease (PD) dominate the pipeline with thousands of active trials, numerous other devastating neurodegenerative conditions remain dramatically underfunded. This analysis examines current clinical trial distribution to identify critical research gaps and priority areas for researchers, funders, and policymakers.
The clinicaltrials.gov database reveals significant disparities in therapeutic development investment across neurodegenerative diseases:
| Disease |
Active/Completed Trials |
Research Investment Level |
| Alzheimer's Disease |
4,903 |
Very High |
| Parkinson's Disease |
4,606 |
Very High |
| Amyotrophic Lateral Sclerosis (ALS) |
1,568 |
Moderate |
| Frontotemporal Dementia (FTD) |
380 |
Low |
| Huntington's Disease |
285 |
Low |
| Multiple System Atrophy (MSA) |
194 |
Very Low |
| Dementia with Lewy Bodies (DLB) |
166 |
Very Low |
| Vascular Dementia (VaD) |
154 |
Very Low |
| Progressive Supranuclear Palsy (PSP) |
154 |
Very Low |
| Corticobasal Degeneration (CBD) |
60 |
Critically Low |
The disparity between disease burden and research investment creates a "pipeline gap" that leaves millions of patients without disease-modifying treatment options.
- AD:PD Ratio: Roughly equal investment (4,903 vs 4,606 trials), reflecting similar disease burden and public attention.
- AD:ALS Ratio: 3:1 ratio despite ALS being equally fatal and having fewer treatment options.
- AD:FTD Ratio: 13:1 despite similar pathophysiology and overlapping clinical features.
- AD:PSP Ratio: 32:1 despite PSP being among the most rapidly progressive neurodegenerative conditions.
- AD:CBD Ratio: 82:1 — the most severe disparity among classic neurodegenerative diseases.
Therapeutic development has concentrated on several well-funded mechanisms:
- Amyloid-targeting: 200+ trials testing monoclonal antibodies, vaccines, and secretase inhibitors
- Tau-targeting: 150+ trials across multiple therapeutic modalities
- Dopaminergic therapies: Extensive PD motor symptom management pipeline
- Neuroinflammation: Growing but still concentrated in AD/PD
Critical biological pathways remain largely untargeted in clinical trials:
| Mechanism |
Current Trial Count |
Priority Level |
| Glial cell biology (astrocytes, microglia) |
<50 |
High |
| Proteostasis/lysosomal pathways |
<30 |
High |
| Metal homeostasis/metal chelation |
<20 |
High |
| Network repair/regeneration |
<15 |
Very High |
| RNA metabolism/alternative splicing |
<10 |
Very High |
| Metabolic dysfunction correction |
<25 |
High |
| Blood-brain barrier modulation |
<15 |
Very High |
-
Corticobasal Degeneration (CBD)
- Rationale: Only 60 trials despite being one of the most aggressive tauopathies
- 4R-tau pathology shared with PSP makes research findings translatable
- Current treatments purely symptomatic
- Recommended focus: Tau-targeting, neuroprotection, rehabilitation
-
Progressive Supranuclear Palsy (PSP)
- Rationale: 154 trials for a disease with 5-7 year median survival
- Strong biological rationale for tau-targeted therapies
- Already validated outcome measures from recent Phase III failures
- Recommended focus: Tau aggregation inhibitors, neuroprotection
-
Multiple System Atrophy (MSA)
- Rationale: 194 trials despite alpha-synuclein pathology affecting multiple systems
- Poor diagnostic accuracy limits clinical trial success
- Critical need for disease-modifying therapies
- Recommended focus: Alpha-synuclein targeting, autonomic dysfunction
-
Dementia with Lewy Bodies (DLB)
- Rationale: 166 trials despite being the second most common neurodegenerative dementia
- Often misdiagnosed as AD or PD, leading to inappropriate trial enrollment
- Critical need for cholinergic and alpha-synuclein-targeted approaches
- Recommended focus: Cholinergic enhancement, sleep-wake cycle modulation
-
Vascular Dementia (VaD)
- Rationale: 154 trials despite being the second most common dementia overall
- Often comorbid with AD, complicating trial design
- Unique opportunity for vascular-modifying interventions
- Recommended focus: Vascular risk factor modification, cerebral perfusion
-
Frontotemporal Dementia (FTD)
- Rationale: 380 trials but spread across heterogeneous subtypes
- TDP-43 and tau pathologies share mechanisms with ALS
- Strong genetic foundation for targeted therapies
- Recommended focus: GRN, MAPT, C9orf72-targeted approaches
-
Huntington's Disease
- Rationale: 285 trials but single-target focus on mutant huntingtin
- Somatic CAG expansion provides novel therapeutic target
- Need for downstream pathway modulation
- Recommended focus: HTT lowering, somatic expansion targeting
-
Amyotrophic Lateral Sclerosis
- Rationale: 1,568 trials but high failure rate
- Molecular heterogeneity underappreciated in trial design
- Critical need for biomarkers and precision medicine approaches
- Recommended focus: Biomarker-driven trial enrichment, combination therapy
- Leverage biological overlaps: Design trials for CBD/PSP that can inform AD tau research and vice versa
- Implement adaptive platform designs: Enable efficient testing of multiple mechanisms across diseases
- Prioritize biomarker enrichment: Use fluid and imaging biomarkers to identify responsive subgroups
- Standardize outcomes: Adopt common data elements across foundations
- Glial biology: Develop microglia and astrocyte-targeted therapeutics
- Proteostasis: Expand lysosomal and ubiquitin-proteasome system modulators
- Network repair: Advance neurorestorative approaches including gene therapy
- Metabolic support: Test mitochondrial and metabolic enhancement strategies
- Increase CBD/PSP funding: Target 10x current investment within 5 years
- Support cross-disease research: Fund initiatives that span multiple conditions
- Prioritize biomarker development: Enable precision medicine approaches
- Require open data sharing: Accelerate knowledge transfer across programs
- Create international registries: Standardized patient cohorts for underfunded conditions
- Fund clinical trial networks: Infrastructure for efficient multi-site studies
- Support regulatory science: Guidance for rare neurodegenerative disease trials
- Develop outcome measure validation: Standardize endpoints across diseases
Several mechanisms show promise across multiple neurodegenerative conditions:
- Tau pathology: Shared across AD, CBD, PSP, FTD — anti-tau therapies have broad applicability
- Alpha-synucleinopathies: PD, DLB, MSA share pathological protein — synuclein-targeted approaches may benefit multiple conditions
- Neuroinflammation: Universal feature across all neurodegenerative diseases — anti-inflammatory approaches need systematic exploration
- Metabolic dysfunction: Implicated in all conditions — metabolic enhancers may provide general neuroprotection
- Protein homeostasis: Lysosomal dysfunction common to many diseases — proteostasis modulators have broad potential
- Convene expert working groups for CBD, PSP, MSA, DLB trial readiness
- Develop disease-specific clinical trial blueprints
- Identify and validate biomarkers for underfunded conditions
- Establish patient registry networks
- Launch 10+ priority trials in critically underfunded conditions
- Achieve regulatory clarity for biomarker-driven enrichment strategies
- Establish public-private partnerships for rare neurodegenerative disease research
- Create training programs for next-generation clinical researchers
- First disease-modifying therapies approved for CBD, PSP, MSA
- Precision medicine approaches routinely used in clinical trials
- Cross-disease mechanism trials become standard
- Patient outcomes measurably improved across all conditions